A novel retinoic acid-resistant acute promyelocytic leukemia model in vitro and in vivo (Review)

International Journal of Molecular Medicine

Volumn 4, Issue 4, 1999, Pages 359-364

  Kizaki, Masahiro ^a   Fukuchi, Yumi ^a   Ikeda, Yasuo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute promyelocytic leukemia; Differentiation; Retinoic acid; Retinoic acid resistance; SCID mouse

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REMISSION; ANIMAL; DISEASE MODEL; DRUG RESISTANCE; MOUSE MUTANT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, SCID; TRETINOIN;

EID: 0033209601     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.4.4.359     Document Type: Article

References (42)

1. de The H, Chomienne C, Lanotte M, Degos L and Dejean A: The t(15; 17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 347: 558-561, 1991.
2. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VVVS, Dmitrovsky E and Evans RM: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARa with a novel putative transcription factor, PML. Cell 66: 663-674, 1991.
3. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I and Pelicci PG: The acute promyelocytic leukemia specific PML/ RARa protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74: 423-431, 1993.
4. Warrell RP Jr, de The H, Wang ZY and Degos L: Acute promyelocytic leukemia. N Engl J Med 329: 177-189, 1993.
5. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 24: 889-895, 1988.
6. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940-954, 1996.
7. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
8. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Glass B, Lin S-C, Heyman R, Rose D, Glass C and Rosenfeld M: A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85: 403-414, 1996.
9. Chakravarti D, La Morte V, Nelson M, Nakajima T, Schulman I, Juguilon H, Montminy M and Evans RM: Role of CBP/p300 in nuclear receptor signaling. Nature 383: 99-103, 1996.
10. Chen H, Lin R, Schütz R, Chakravarti D, Nash A, Nagy L, Privalsky M, Nakatani Y and Evans RM: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimetric activation complex with P/CAF and CBP/p300. Cell 90: 569-580, 1997.
11. Koeffler HP: Induction of differentiation of human acute myelogenous leukemic cells: therapeutic implications. Blood 62: 709-721, 1983.
12. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu HT and Wang ZY: Use of all-frans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988.
13. Castaigne S, Chomienne C, Daniel MT, Ballarini P, Berger R, Fenaux P and Degos L: Al\-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76: 1704-1709, 1990.
14. Warrell RP Jr, Frankel SR, Miller WH Jr, Sheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS and Dmitrovski E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (allrrans- retinoic acid). N Engl J Med 324: 1385-1393, 1991.
15. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoka H, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T and Ohno R: A\l-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85: 1202-1206, 1995.
16. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr and Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811-814, 1998.
17. Grignani F, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S and Pelicci PG: Fusion proteins of the retinoic acid receptor - A recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815-818, 1998.
18. He L-Z, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A and Pandolfi FF: Distinct interactions of PML-RARa and PLZFRARa with co-repressors determine differential responses to RA in APL. Nat Genet 18: 126-135, 1998.
19. Guidez F, Ivins S, Zhu J, Söderström M, Waxman S and Zelent A: Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARa underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91:2634-2642, 1998.
20. Fenaux P, Chomienne C and Degos L: Acute promyelocytic leukemia: biology and treatment. Semin Oncol 24: 92-102, 1997.
21. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A and Lo Coco F: Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined a\\-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90: 1014-1021, 1997.
22. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM and Wiernik PH: h\\-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-1028, 1997.
23. Kizaki M, Ueno H, Matsushita H, Takayama N, Muto A, Awaya N and Ikeda Y: Retinoid resistance in leukemic cells. Leuk Lymphoma 25: 427-434, 1997.
24. Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler HP and Ikeda Y: Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 87: 725-733, 1996.
25. Delva L, Cornic M, Balitrand N, Guidez F, Miclea J, Delmar A, Teillet F, Fenaux P, Castaigne S, Degos L and Chomienne C: Resistance to ail-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro sensitivity and cellular binding protein levels in leukemic cells. Blood 82: 2175-2181, 1993.
26. Imaizumi M, Suzuki H, Yoshinari M, Sato A, Saito T, Sugawara A, Tsuchiya S, Hatae Y, Fujimoto T, Kakizuka A, Konno T and Iinuma K: Mutations in the E-domain of RARa portion of the PML/RARa chimeric gene may confer clinical resistance to a\\-trans retinoic acid in acute promyelocytic leukemia. Blood 92: 374-382, 1998.
27. Ding W, Li YP, Nobile LH, Grills G, Carrera I, Paietta E, Tallman MS, Wiernik PH and Gallagher RE: Leukemic cellular retinoic acid resistance and missense mutations in the PMLRARa fusion gene after relapse of acute promyelocytic leukemia from treatment with aW-trans retinoic acid and sensitive chemotherapy. Blood 92: 1172-1183, 1998.
28. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F and Berger R: NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086, 1991.
29. Kizaki M, Matsushita H, Takayama N, Muto A, Ueno H, Awaya N, Kawai Y, Asou H, Kamada N and Ikeda Y: Establishment of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood 88: 1824-1833, 1996.
30. Dick JE, Pflumio F and Lapidot T: Mouse models for human hematopoiesis. Semin Immunol 3: 367-378, 1991.
31. Uckun FM: Severe combined immunodeficient mouse models of human leukemia. Blood 88: 1135-1146, 1996.
32. Miyakawa Y, Fukuchi Y, Ito M, Kobayashi K, Kuramochi K, Ikeda Y, Takebe Y, Tanaka T, Miyasaka M, Nakahata T, Tamaoki N, Nomura T, Ueyama Y and Shimamura K: Establishment of human granulocyte-macrophage colony stimulating factor producing transgenic SCID mice. Br J Haematol 95: 437-442, 1996.
33. Altabef M, Garcia M, Lavau C, Bae S-C, Dejean A and Samarut J: A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARa fusion genes transforms hematopoietic progenitors in vitro and induces acute leukemia. EMBO J 15: 2707-2716, 1996.
34. Early E, Moore MAS, Kakizuka A, Nason-Burchenal K, Martin P and Evans RM: Transgenic expression of PML-RARa impaires myelopoiesis. Proc Natl Acad Sei USA 93: 7900-7904, 1996.
35. He L-Z, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soarés V, Cattoretti C and Pandolfi PP: Acute leukemia with promyelocytic features in PML/RARa transgenic mice. Proc Natl Acad Sei USA 94: 5302-5307, 1997.
36. Grisolano JL, Wesselschmidt RL, Pelicci PG and Ley TJ: Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARa under control of cathepsin G regulatory sequences. Blood 89: 376-387, 1997.
37. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S and Bishop JM: A PML-RARa transgene initiate murine promyelocytic leukemia. Proc Natl Acad Sei USA 94: 2551-2556, 1997.
38. Zhang SY, Zhu J, Chen GQ, Du XX, Lu LJ, Zhang Z, Zhang HJ, Chen HR, Wang ZY, Berger R, Lanotte M, Waxman S, Chen Z and Chen SJ: Establishment of a human promyelocytic leukemiaascites model in SCID mice. Blood 87: 3404-3409, 1996.
39. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z and Wang ZY: Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficiency and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
40. Soignet SL, Maslak P, Wang ZG, Thanwar S, Calleja E, Dardashti LJ, Corso D, De Blasio A, Gabrilove J, Scheinberg DA, Pandorfi PP and Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998.
41. 41 Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY and Chen Z: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cells apoptosis with downregulation of bcl-2 expression and modulation of PML-RARa/PML proteins. Blood 88: 1052-1061, 1996.
42. Kizaki M, Muto A, Kinjo K, Ueno H and Ikeda Y: Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia. J Natl Cancer Inst 90: 1906-1907, 1998.